Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns about ...

Beam Therapeutics shares were 10% higher, at $31.06, after the company swung to a fourth-quarter profit, and announced a $500 million strategic financing facility.

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, RBC Capital adjusted the price target on Beam Therapeutics Inc. (NASDAQ:BEAM ...

Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 ...

First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam’s Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of ...

Beam Therapeutics (NASDAQ:BEAM) is one of the 17 biotechnology stocks with more than 50% upside. On January 22, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Beam Therapeutics ...

Fintel reports that on March 10, 2025, Jones Trading upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Hold to Buy. Analyst Price Forecast Suggests 92.72% Upside As of March 4, 2025, ...

Recently, BEAM reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. Unfortunately, they concurrently announced a $500 million equity offering, which may have ...